{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:10:42Z","timestamp":1788844242870,"version":"build-2803163510"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Current recommendations for hematologic response (HemR) assessment in monoclonal gammopathies of renal significance (MGRS) are based on the monoclonal immunoglobulin (MIg) component responsible for renal damage. Light-chain (LC) amyloidosis criteria are recommended when renal lesions are due to LC, whereas multiple myeloma (MM) criteria are proposed when due to an intact monoclonal immunoglobulin. However, the nephrotoxic MIg is frequently not measurable either by the International Myeloma Working Group (IMWG) or the International Society of Amyloidosis (ISA) criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the study shown below, we retrospectively analyzed an original multi-center series of 45 MGRS patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-two MGRS-non-amyloidosis (MGRS-NA) and 13 MGRS-amyloidosis (MGRS-A) patients were included. Twelve (37.5%) and 15 (47%) MGRS-NA patients had measurable disease by either the IMWG or ISA criteria, respectively. According to the IMWG criteria, 5% of MGRS-NA patients with intact MIg renal deposits and 80% with exclusively LC deposits had measurable disease, as determined by serum electrophoresis or sFLC assay, respectively. Based on the ISA criteria, 35 and 80% of MGRS-NA patients with MIg and LC renal deposits, respectively, had measurable disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our findings reveal the limitations of the current proposed HemR assessment in MGRS-NA patients and explore potential alternatives to ease clinical practice and guideline development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1902202","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:27:02Z","timestamp":1788841622000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hematologic response assessment in monoclonal gammopathy of renal significance: critical appraisal of current criteria"],"prefix":"10.3389","volume":"13","author":[{"given":"A.","family":"Domingo-Gonz\u00e1lez","sequence":"first","affiliation":[{"name":"Department of Hematology, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital","place":["Madrid, Spain"]},{"name":"Health Research Institute, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cannata-Ortiz","sequence":"additional","affiliation":[{"name":"Department of Pathology, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fern\u00e1ndez-Prado","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Velasco-Valdazo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rey Juan Carlos University Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Men\u00e9ndez-Cuevas","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rey Juan Carlos University Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Martos","sequence":"additional","affiliation":[{"name":"Department of Hematology, General de Villalba Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pav\u00eda Pascual","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Prieto Pareja","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Naya","sequence":"additional","affiliation":[{"name":"Department of Hematology, Infanta Elena Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Garc\u00eda Corral","sequence":"additional","affiliation":[{"name":"Department of Clinical Analysis, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Mah\u00edllo-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Health Research Institute, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz","place":["Madrid, Spain"]},{"name":"Division of Statistics and Epidemiology, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Llamas Sillero","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital","place":["Madrid, Spain"]},{"name":"Health Research Institute, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Sol\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital","place":["Madrid, Spain"]},{"name":"Health Research Institute, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Askari","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital","place":["Madrid, Spain"]},{"name":"Health Research Institute, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","article-title":"Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the international kidney and monoclonal Gammopathy research group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1056\/NEJMra1810907","article-title":"Monoclonal Gammopathy of renal significance","volume":"384","author":"Leung","year":"2021","journal-title":"N Engl J Med"},{"key":"ref4","first-page":"243","article-title":"Monoclonal gammopathy of renal significance (MGRS): histopathologic classification, diagnostic workup, and therapeutic options","volume":"77","author":"Amaador","year":"2019","journal-title":"Neth J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1182\/blood-2013-05495929","article-title":"How I treat monoclonal gammopathy of renal significance (MGRS)","volume":"122","author":"Fermand","year":"2013","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"8577","DOI":"10.2147\/IJGM.S386733","article-title":"A review on the diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits","volume":"15","author":"Lin","year":"2022","journal-title":"Int J Gen Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/bjh.17052","article-title":"Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance","volume":"193","author":"Kastritis","year":"2021","journal-title":"Br J Haematol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/ajh.26566","article-title":"Monoclonal gammopathy of renal significance (MGRS): real-world data on outcomes and prognostic factors","volume":"97","author":"Gozzetti","year":"2022","journal-title":"Am J Hematol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMra2304088","article-title":"Systemic light chain amyloidosis","volume":"390","author":"Sanchorawala","year":"2024","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2020.1868810","article-title":"Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis","volume":"28","author":"Palladini","year":"2021","journal-title":"Amyloid"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12882-023-03256-5","article-title":"Discordance of light chain isotypes between serum and glomerular deposits in proliferative glomerulonephritis with monoclonal IgG deposits: a case report and review of the literature","volume":"24","author":"Miura","year":"2023","journal-title":"BMC Nephrol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41408-025-01340-7","article-title":"Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis","volume":"15","author":"Askari","year":"2025","journal-title":"Blood Cancer J"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000526244","article-title":"Monoclonal Gammopathy of renal significance: Histomorphological Spectrum at a tertiary care center","volume":"2","author":"Barwad","year":"2022","journal-title":"Glomerular Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/nep.13633","article-title":"Renal pathologic spectrum and clinical outcome of monoclonal gammopathy of renal significance: a large retrospective case series study from a single institute in China","volume":"25","author":"Yu","year":"2020","journal-title":"Nephrology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12882-024-03458-5","article-title":"Systematic review and meta-analysis of the clinical features of MGRS","volume":"25","author":"Du","year":"2024","journal-title":"BMC Nephrol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/ajh.26801","article-title":"Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: emphasizing the need for a consensus approach","volume":"98","author":"Pianko","year":"2023","journal-title":"Am J Hematol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1681\/ASN.2020101541","article-title":"Safety and efficacy of Daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits","volume":"32","author":"Zand","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/ki.2015.201","article-title":"Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease","volume":"88","author":"Cohen","year":"2015","journal-title":"Kidney Int"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1902202\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:27:03Z","timestamp":1788841623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1902202\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":20,"alternative-id":["10.3389\/fmed.2026.1902202"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1902202","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1902202"}}